CRMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
CorMedix Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.38+0.12 (+1.65%)
Close on Oct 19, 2026
- Market cap
- $682.50M
- P/E (TTM)
- 3.6
- Dividend yield
- –
CorMedix Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Product sales, net | $304.34M | $43.47M | – | – | – | – | – | 97.6% | +600.1% |
| Defen Cath | $258.81M | $43.47M | – | – | – | – | – | 83.0% | +495.4% |
| Melinta Portfolio | $45.53M | – | – | – | – | – | – | 14.6% | – |
| Contract revenue | $7.37M | – | – | – | – | – | – | 2.4% | – |
By region
| Revenue | FY2025 | FY2024 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| European and Mideast operations | – | – | – | – | $274.44K | $420.97K | $320.50K | – | – |
| European and Mideast operations [Member] | – | – | $190.94K | $237.03K | $274.44K | – | – | – | – |
From the segment and revenue-disaggregation notes of CorMedix's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.